Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2021

20.08.2020 | Original Article

Perceived Barriers to Treatment in Persons Treated for Functional Gastrointestinal Disease with Constipation

verfasst von: Klaus Bielefeldt

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Despite expanding treatment options, patients with functional gastrointestinal disorders (FGID) frequently express concerns about problems with access to care. We hypothesized that health insurance coverage contributes to the perceived problems with care delivery.

Methods

Using the Medical Expenditure Panel Survey, we examined a cohort of participants defined by the diagnosis code for FGID plus the recorded prescription for laxative therapy. Demographic data, healthcare utilization and cost, insurance coverage, comorbid conditions, and information about provider characteristics were extracted for the years 2005–2015. Age- and sex-matched controls were identified for each year included. Barriers to care were based on responses to questions about inability to receive timely care or medication. Logistic regression was used to identify independent predictors of perceived barriers.

Results

The cohort was female predominant (67.8%; mean age: 58.8 ± 0.33 years) with 15.4% reporting problems with access to care. Limited insurance coverage was most commonly cited by respondents. Consistent with this result, uninsured persons were significantly more likely to report barriers to care, while the type of insurance for those covered did not independently predict access problems. In addition, comorbidity burden and provider-specific factors, such as available contact options or insufficient explanations, correlated with perceived barriers to care delivery.

Conclusion

While the study design cannot establish causal links, persons with FGID commonly report access problems, which correlate with lack of health insurance and comorbidities. Providers can influence this perception by offering more flexible office hours and incorporating patient expectations related to treatment explanations and shared decision-making.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591.CrossRef Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591.CrossRef
2.
Zurück zum Zitat Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology. 1990;98:336–340. Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology. 1990;98:336–340.
3.
Zurück zum Zitat Herrick LM, Spalding WM, Saito YA, et al. A case–control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ. 2017;20:273–279.CrossRef Herrick LM, Spalding WM, Saito YA, et al. A case–control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ. 2017;20:273–279.CrossRef
4.
Zurück zum Zitat Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69.CrossRef Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69.CrossRef
5.
Zurück zum Zitat DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27:2213–2222.CrossRef DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27:2213–2222.CrossRef
6.
Zurück zum Zitat Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17:2471–2478.e3.CrossRef Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17:2471–2478.e3.CrossRef
7.
Zurück zum Zitat Shah ED, Saini SD, Chey WD. Value-based pricing for Rifaximin increases access of patients with irritable bowel syndrome with diarrhea to therapy. Clin Gastroenterol Hepatol. 2019;17:2687–2695.e11.CrossRef Shah ED, Saini SD, Chey WD. Value-based pricing for Rifaximin increases access of patients with irritable bowel syndrome with diarrhea to therapy. Clin Gastroenterol Hepatol. 2019;17:2687–2695.e11.CrossRef
8.
Zurück zum Zitat Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155:1753–1763.CrossRef Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155:1753–1763.CrossRef
9.
Zurück zum Zitat Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome—a systematic review. Gastroenterology. 2019;157:97–108.CrossRef Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome—a systematic review. Gastroenterology. 2019;157:97–108.CrossRef
10.
Zurück zum Zitat Ford AC, Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21–39.CrossRef Ford AC, Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21–39.CrossRef
11.
Zurück zum Zitat Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol. 2004;16:995–1001.CrossRef Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol. 2004;16:995–1001.CrossRef
12.
Zurück zum Zitat McCormick JB, Hammer RR, Farrell RM, et al. Experiences of patients with chronic gastrointestinal conditions: in their own words. Health Qual Life Outcomes. 2012;10:25.CrossRef McCormick JB, Hammer RR, Farrell RM, et al. Experiences of patients with chronic gastrointestinal conditions: in their own words. Health Qual Life Outcomes. 2012;10:25.CrossRef
13.
Zurück zum Zitat Gudleski GD, Satchidanand N, Dunlap LJ, et al. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther. 2017;88:65–75.CrossRef Gudleski GD, Satchidanand N, Dunlap LJ, et al. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther. 2017;88:65–75.CrossRef
14.
Zurück zum Zitat Hurst N, Ruta D, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Rheumatology. 1998;37:862–869.CrossRef Hurst N, Ruta D, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Rheumatology. 1998;37:862–869.CrossRef
15.
Zurück zum Zitat Lacy B, Ayyagari R, Guerin A, et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol. 2019;12:1756284818818326.PubMedPubMedCentral Lacy B, Ayyagari R, Guerin A, et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol. 2019;12:1756284818818326.PubMedPubMedCentral
16.
Zurück zum Zitat Bernard DM, Johansson P, Fang Z. Out-of-pocket healthcare expenditure burdens among nonelderly adults with hypertension. Am J Manag Care. 2014;20:406–413.PubMed Bernard DM, Johansson P, Fang Z. Out-of-pocket healthcare expenditure burdens among nonelderly adults with hypertension. Am J Manag Care. 2014;20:406–413.PubMed
17.
Zurück zum Zitat Hamman MK, Kapinos KA. Affordable care act provision lowered out-of-pocket cost and increased colonoscopy rates among men in medicare. Health Aff (Millwood). 2015;34:2069–2076.CrossRef Hamman MK, Kapinos KA. Affordable care act provision lowered out-of-pocket cost and increased colonoscopy rates among men in medicare. Health Aff (Millwood). 2015;34:2069–2076.CrossRef
18.
Zurück zum Zitat Vakil N, Stelwagon M, Shea EP, et al. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United Eur Gastroenterol J. 2016;4:413–422.CrossRef Vakil N, Stelwagon M, Shea EP, et al. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United Eur Gastroenterol J. 2016;4:413–422.CrossRef
19.
Zurück zum Zitat Weerts Z, Vork L, Mujagic Z, et al. Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2019;31:e13629.CrossRef Weerts Z, Vork L, Mujagic Z, et al. Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2019;31:e13629.CrossRef
20.
Zurück zum Zitat Lackner JM, Gudleski GD, Thakur ER, et al. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am J Gastroenterol. 2014;109:224–233.CrossRef Lackner JM, Gudleski GD, Thakur ER, et al. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am J Gastroenterol. 2014;109:224–233.CrossRef
21.
Zurück zum Zitat Ward BW. Barriers to Health Care for Adults With Multiple Chronic Conditions: United States, 2012–2015. NCHS Data Brief 2017:1–8. Ward BW. Barriers to Health Care for Adults With Multiple Chronic Conditions: United States, 2012–2015. NCHS Data Brief 2017:1–8.
22.
Zurück zum Zitat Solheim AM, Mygland A, Ljostad U. Quality of multiple sclerosis out-patient health care services with focus on patient reported experiences. BMC Res Notes. 2017;10:250.CrossRef Solheim AM, Mygland A, Ljostad U. Quality of multiple sclerosis out-patient health care services with focus on patient reported experiences. BMC Res Notes. 2017;10:250.CrossRef
23.
Zurück zum Zitat Kurichi JE, Pezzin L, Streim JE, et al. Perceived barriers to healthcare and receipt of recommended medical care among elderly Medicare beneficiaries. Arch Gerontol Geriatr. 2017;72:45–51.CrossRef Kurichi JE, Pezzin L, Streim JE, et al. Perceived barriers to healthcare and receipt of recommended medical care among elderly Medicare beneficiaries. Arch Gerontol Geriatr. 2017;72:45–51.CrossRef
24.
Zurück zum Zitat Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23:2986–3000.PubMed Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23:2986–3000.PubMed
25.
Zurück zum Zitat Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm. 2016;22:122–130.PubMed Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm. 2016;22:122–130.PubMed
26.
Zurück zum Zitat Doshi JA, Li P, Huo H, et al. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J Clin Oncol. 2018;36:476–482.CrossRef Doshi JA, Li P, Huo H, et al. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J Clin Oncol. 2018;36:476–482.CrossRef
27.
Zurück zum Zitat Straus WL, Eisen GM, Sandler RS, et al. Crohn’s disease: does race matter? The Mid-Atlantic Crohn’s Disease Study Group. Am J Gastroenterol. 2000;95:479–483.CrossRef Straus WL, Eisen GM, Sandler RS, et al. Crohn’s disease: does race matter? The Mid-Atlantic Crohn’s Disease Study Group. Am J Gastroenterol. 2000;95:479–483.CrossRef
28.
Zurück zum Zitat Johnson PJ, Carlson KF, Hearst MO. Healthcare disparities for American Indian veterans in the United States: a population-based study. Med Care. 2010;48:563–569.CrossRef Johnson PJ, Carlson KF, Hearst MO. Healthcare disparities for American Indian veterans in the United States: a population-based study. Med Care. 2010;48:563–569.CrossRef
29.
Zurück zum Zitat Finkelstein SR, Liu N, Rosenthal D, et al. When open access might not work: understanding patient attitudes in appointment scheduling. Health Care Manag Rev. 2018;43:348–358.CrossRef Finkelstein SR, Liu N, Rosenthal D, et al. When open access might not work: understanding patient attitudes in appointment scheduling. Health Care Manag Rev. 2018;43:348–358.CrossRef
30.
Zurück zum Zitat Greenhouse DL, Probst JC. After-hours telephone calls in a family practice residency: volume, seriousness, and patient satisfaction. Fam Med. 1995;27:525–530.PubMed Greenhouse DL, Probst JC. After-hours telephone calls in a family practice residency: volume, seriousness, and patient satisfaction. Fam Med. 1995;27:525–530.PubMed
31.
Zurück zum Zitat Quigley BM, Sova CC, Brenner DM, et al. (Can’t Get No) patient satisfaction: the predictive power of demographic, GI, and psychological factors in IBS patients. J Clin Gastroenterol. 2018;52:614–621.CrossRef Quigley BM, Sova CC, Brenner DM, et al. (Can’t Get No) patient satisfaction: the predictive power of demographic, GI, and psychological factors in IBS patients. J Clin Gastroenterol. 2018;52:614–621.CrossRef
32.
Zurück zum Zitat Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237–248.CrossRef Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237–248.CrossRef
33.
Zurück zum Zitat Murphy M, Hollinghurst S, Turner K, et al. Patient and practitioners’ views on the most important outcomes arising from primary care consultations: a qualitative study. BMC Fam Pract. 2015;16:108.CrossRef Murphy M, Hollinghurst S, Turner K, et al. Patient and practitioners’ views on the most important outcomes arising from primary care consultations: a qualitative study. BMC Fam Pract. 2015;16:108.CrossRef
34.
Zurück zum Zitat Sibelli A, Moss-Morris R, Chalder T, et al. Patients’ perspectives on GP interactions after cognitive behavioural therapy for refractory IBS: a qualitative study in UK primary and secondary care. Br J Gen Pract. 2018;68:e654–e662.CrossRef Sibelli A, Moss-Morris R, Chalder T, et al. Patients’ perspectives on GP interactions after cognitive behavioural therapy for refractory IBS: a qualitative study in UK primary and secondary care. Br J Gen Pract. 2018;68:e654–e662.CrossRef
36.
Zurück zum Zitat Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits. 2014;7:289–297.PubMedPubMedCentral Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits. 2014;7:289–297.PubMedPubMedCentral
Metadaten
Titel
Perceived Barriers to Treatment in Persons Treated for Functional Gastrointestinal Disease with Constipation
verfasst von
Klaus Bielefeldt
Publikationsdatum
20.08.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06544-4

Weitere Artikel der Ausgabe 3/2021

Digestive Diseases and Sciences 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.